Response to “Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment”
figure
posted on 2020-08-03, 10:24authored byAnne B. Brooks, Jakob Langer, Tommi Tervonen, Mads Peter Hemmingsen, Kosei Eguchi, Elizabeth D. Bacci
Article full
text
There are currently no digital features for this article. For a full
list of declarations, including funding and author disclosure statements,
please see the full text online (see “read the peer-reviewed publication”
opposite).